The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

DM Hyman, TW Laetsch, S Kummar, SG DuBois… - 2017 - ascopubs.org
DM Hyman, TW Laetsch, S Kummar, SG DuBois, AF Farago, AS Pappo, GD Demetri…
2017•ascopubs.org
LBA2501 The full, final text of this abstract will be available at abstracts. asco. org at 7: 30
AM (EDT) on Saturday, June 3, 2017, and in the Annual Meeting Proceedings online
supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the
Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
LBA2501
The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, June 3, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
ASCO Publications
Show moreShow less
Save Cite Cited by 111 Related articles All 2 versions